Novel compound with platelet aggregation inhibitor activity
CA 2136007 C · Owner: Shimizu, Masaro · Inventors: Miura, Tomoaki; Shitara, Eiki; Shimizu, Masaro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed:, (see formula I), wherein, R1 represents a group -W-(CH2)i-COOR3 R2 represents a hydrogen atom or a group -W-(CH2)i-COOR3 or - OR4, X represents -CH= or -N=, Y represents (i) a group -(CO)k-N(R5)-Z-, wherein Z represents a bond or a group -(CH2)m-CO- or a group -(CH2)m-CHR6- (ii) a group -(CH2)m-N(R5)-(CO)k-, or, (iii) a group -(CO)k-Het wherein Het represents a five- or sixmembered heterocyclic ring comprising a nitrogen atom A represents, (i) the following groups (II) (III) or (IV), B represents a bond, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 1994 and granted December 14, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 17, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.